Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Endogenous Metabolite
    (1)
  • PGE Synthase
    (1)
  • Prostaglandin Receptor
    (1)
  • Others
    (27)
Filter
Search Result
Results for "

pge1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    29
    TargetMol | Inhibitors_Agonists
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
Prostaglandin E1
PGE1, Alprostadil
T1626745-65-3
Prostaglandin E1 (Alprostadil) is the naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions. Prostaglandin E1 is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.
  • Inquiry Price
Size
QTY
15-epi-PGE1
15(R)-Prostaglandin E1,15-Epiprostaglandin E1
T8538620897-91-0
15-epi-PGE1 (15R-Prostaglandin E1; 15-Epiprostaglandin E1), a stereoisomer of PGE1, exhibits reduced biological activity [2]. This compound acts as a non-competitive inhibitor of human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH), with an inhibitory concentration 50 (IC50) value of 170 μM [1].
  • Inquiry Price
10-14 weeks
Size
QTY
Limaprost
OP1206, ONO1206, 17α,20-dimethyl-δ2-PGE1
T1575774397-12-9
Limaprost (17α,20-dimethyl-δ2-PGE1) is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency.It is a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost (17α,20-dimethyl-δ2-PGE1) can be used for pain relief, has antianginal effects, and has potential for ischaemic symptoms treatment.
  • Inquiry Price
Size
QTY
Alprostadil sodium
PGE1 sodium salt,Prostaglandin E1 sodium
T2990727930-45-6
Alprostadil sodium is a prostaglandin receptor ligand with Ki values of 36, 10, 1.1, 2.1, and 33 nM for EP1, EP2, EP3, EP4, and IP, respectively, in mice.It induces vasodilatation and inhibits platelet aggregation, and it can be used as a vasodilator for the study of peripheral vascular disease.
  • Inquiry Price
Size
QTY
Alprostadil ethyl ester
Prostaglandin E1 ethyl ester,PGE1 ethyl ester
T2990835900-16-4
Alprostadil ethyl ester is a biochemical used in the treatment of scleroderma.
  • Inquiry Price
Size
QTY
SC 31391
SC-31391, SC31391
T34550144730-93-8
SC 31391 is a PGE1 analog.
  • Inquiry Price
10-14 weeks
Size
QTY
13,14-dihydro-15-keto Prostaglandin E1
13,14-dihydro-15-keto Prostaglandin E1
T361475094-14-4
13,14-dihydro-15-keto Prostaglandin E1 inhibits ADP-induced platelet aggregation in human isolated platelet-rich plasma (IC50=14.8 μg mL) and is a PGE1 metabolite.
  • Inquiry Price
Size
QTY
15(S)-15-methyl Prostaglandin E2
15(S)-15-methyl Prostaglandin E2
T3615435700-27-7
15(S)-15-methyl PGE2 is a potent, metabolically stable analog of PGE2. It is a potent gastric antisecretory and antiulcer compound. 15(S)-15-methyl PGE2 binds to human myometrium with twice the affinity of PGE2 and is ten times more potent than PGE1 in contracting uterine smooth muscle.
  • Inquiry Price
Size
QTY
8-iso Prostaglandin A1
8-iso Prostaglandin A1
T36157211186-29-7
8-iso Prostaglandin A1 (8-iso PGA1) is an isoprostane and a member in a large family of prostanoids of non-cyclooxygenase origin. It occurs as a common minor impurity in most commercial preparations of PGE1. The biological activity of 8-iso PGA1 has not been studied in depth or reported in the literature.
  • Inquiry Price
Size
QTY
8-iso-15-keto Prostaglandin F2β
8-iso-15-keto Prostaglandin F2β
T361671621482-36-7
8-iso Prostaglandin F2β (8-iso PGF2β) is an isomer of PGF2α of non-enzymatic origin. It is one of 64 possible isomers of PGF2α which can be produced by free radical peroxidation of arachidonic acid. 8-iso PGF2β exhibits very weak contraction of human umbilical vein artery and does not promote aggregation of human whole blood. However, 8-iso PGF2β moderately contracts both the canine and porcine pulmonary vein, although the effect is much weaker than that exhibited by other isoprostanes such as 8-iso PGE1, 8-iso PGE2, or 8-iso PGF2α. 8-iso-15-keto PGF2β is a potential metabolite of 8-iso PGF2β via the 15-hydroxy PG dehydrogenase pathway. There are no published reports on the formation or biological activity of 8-iso-15-keto PGF2β.
  • Inquiry Price
Size
QTY
15-keto Prostaglandin A1
15-keto Prostaglandin A1
T3620961600-67-7
Prostaglandin A1 (PGA1) was first isolated as a dehydration product of the PGE1 compounds found in human semen. 15-keto PGA1 is a metabolite of PGA1, produced by 15-hydroxy PG dehydrogenase. It can be produced from PGA1 in pig lung, trachea, aorta, and pulmonary artery tissue preparations. 15-keto PGA1, given at a concentration of 6 μM, causes vasoconstriction of rabbit lung that is comparable to that induced by angiotensin II.
  • Inquiry Price
Size
QTY
16,16-dimethyl Prostaglandin E1
16,16-dimethyl Prostaglandin E1
T3621441692-15-3
16,16-dimethyl Prostaglandin E1 is a PGE1 (T1626) analog that induces bronchoconstriction and vascular smooth muscle contraction and inhibits indomethacin-induced cell elongation.
  • Inquiry Price
Size
QTY
6-keto Prostaglandin E1
6-keto Prostaglandin E1
T3672667786-53-2
6-keto Prostaglandin E1 is a bioactive derivative of PGE1 that plays a role in antiplatelet aggregation and depolymerization.
  • Inquiry Price
Size
QTY
13,14-dihydro Prostaglandin E1
13,14-dihydro Prostaglandin E1
T3677519313-28-1
13,14-dihydro Prostaglandin E1 (13,14-dihydro PGE1) is a biologically active metabolite of PGE1 with comparable potency to the parent compound. It is an inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC50 values of 31 and 21 nM, respectively. 13,14-dihydro PGE1 is a slightly more potent inhibitor of ADP-induced human platelet aggregation than PGE1 which has an IC50 value of 40 nM. Also, 13,14-dihydro PGE1 was shown to activate adenylate cyclase in NCB-20 hybrid cells with a Kact value of 668 nM.
  • Inquiry Price
Size
QTY
(±)14(15)-EpEDE
T37233351533-80-7
8,11,14-Eicosatrienoic acid, also known as dihomo-γ-linolenic acid , is a polyunsaturated fatty acid (PUFA) produced from γ-linolenic acid by the action of fatty acid elongases. It can be metabolized by the cyclooxygenase pathway to produce 1-series prostaglandins (PGs) (e.g., PGE1). (±)14(15)-EpEDE is an EpEDE acid formed from 8,11,14-eicosatrienoic acid. This monoepoxide can be generated from the PUFA, in vitro, by the action of a strong oxidizing agent. Alternatively, this compound may be produced, in vivo, by epoxidation of the PUFA by cytochrome P450 epoxygenases. The biological properties of this compound are poorly understood.
  • Inquiry Price
Size
QTY
KMN-80
T374411628759-75-0
The prostaglandin E receptor 4 (EP4) is one of four G protein-coupled receptors that mediate the actions of prostaglandin E2 . Binding of PGE2 to the EP4 receptor causes an increase in intracellular cyclic AMP, which plays important roles in bone formation and resorption, cancer, and atherosclerosis. KMN-80 is a substituted γ-lactam (pyrrolidinone) derivative of PGE1 that acts as a selective and potent agonist of EP4 with an IC50 value of 3 nM (IC50 = 1.4 μM for EP3 and > 10 μM for all other prostanoid receptors). In functional assays it has been shown to stimulate secreted alkaline phosphatase gene reporter activity in EP4-transfected HEK293 cells with an EC50 value of 0.19 nM, demonstrating >5,000 and 50,000-fold selectivity against EP2 and TP, respectively. KMN-80 can induce the differentiation of bone marrow stem cells from both young and aged rats into osteoblasts in vitro (EC50s = 20 and 153 nM, respectively) and exhibits favorable tolerability up to at least 10 μM, whereas the EP4 agonist L-902,688 is highly cytotoxic at similar concentrations in these cells. KMN-80 has been used to repair calvarial defects in an in vivo rat craniomaxillofacial reconstruction model (rate of reduction in defect size equivalent to BMP-2 treated rats) and to promote bone formation in a rat incisor tooth socket model.
  • Inquiry Price
10-14 weeks
Size
QTY
tetranor-PGEM
tetranor-Prostaglandin E Metabolite,tetranor-PGEM
T3777324769-56-0
tetranor-PGEM is the major urinary metabolite of PGE1 and PGE2, and is used as a marker of PGE2 biosynthesis.[1],[2] About 15% of an infused dose of PGE2 appears as this metabolite in the urine of humans. Normal healthy males excrete 7-40 μg of tetranor-PGEM over a 24-hour period.[1]
  • Inquiry Price
Size
QTY
MRS2395
T62532491611-55-3
MRS2395 is a dipivaloyl derivative and a potent antagonist of the P2Y12 receptor. MRS2395 inhibited ADP-induced platelet activation (Ki: 3.6 μM). MRS2395 enhances platelet dense granule release in response to TRAP-6.
  • Inquiry Price
6-8 weeks
Size
QTY
BMY-42393
T70865136451-58-6
BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. BMY 42393 competed for radiolabeled iloprost and PGE1 binding to platelet membranes (IC50; 170 nM and 130 nM, respectively).
  • Inquiry Price
8-10 weeks
Size
QTY
SC 34301
Enisoprost
T7334681026-63-3
SC 34301 (Enisoprost), a potent and orally active prostaglandin E1 (PGE1) analog, significantly enhances survival rates and reduces bacterial translocation in burned mice.
  • Inquiry Price
8-10 weeks
Size
QTY
Rp-Adenosine-5'-O-(1-thiotriphosphate) sodium
Rp-ATP-α-S
T83807
Rp-Adenosine-5'-O-(1-thiotriphosphate) (Rp-ATP-α-S), a sulfur-containing nucleotide derivative isomer and a purinergic P2Y1 receptor agonist, promotes calcium mobilization in HEK293 cells expressing the human P2Y1 receptor (EC50 = 75 nM). This compound exhibits binding affinity to washed isolated human platelets (Ki = 156 nM) and attenuates ADP-induced aggregation in human platelet-rich plasma (PRP; pA2 = 4.74), as well as inhibits cAMP production triggered by prostaglandin E1 (PGE1) in human PRP (pA2 = 5.26). Furthermore, it triggers relaxation in carbamoylcholine-constricted guinea pig taenia coli strips (EC50 = 56 nM). Rp-ATP-α-S also contributes to the synthesis of cyclic dinucleotides, recognized by bacterial riboswitches.
  • Inquiry Price
3-6 months
Size
QTY
13,14-dihydro-16,16-difluoro Prostaglandin E1
15-hydroxy Lubiprostone
T84513475992-30-4
Prostaglandin E1 (PGE1), synthesized through cyclooxygenase-mediated metabolism of dihomo-γ-linolenic acid (DGLA), functions by inhibiting platelet aggregation (IC50= 40 nM) and enhancing vasodilation. Its analog, 13,14-dihydro-16,16-difluoro PGE1, and the metabolite, 13,14-dihydro PGE1, both retain similar anti-aggregatory properties to the original compound. The inclusion of two electron-withdrawing fluorine atoms in 13,14-dihydro-16,16-difluoro PGE1 is believed to increase molecular stability and potentially extend bioavailability by resisting hydrolytic degradation.
  • Inquiry Price
8-10 weeks
Size
QTY
13,14-dihydro-15(R)-Prostaglandin E1
13,14-dihydro-15(R)-PGE1
T84527201848-10-4
13,14-Dihydro-15(R)-Prostaglandin E1 (13,14-dihydro-15(R)-PGE1) is an analog of 13,14-dihydro-PGE1 characterized by its R-configured hydroxyl group at the C-15 position [1].
  • Inquiry Price
8-10 weeks
Size
QTY
13,14-dihydro-19(R)-hydroxy Prostaglandin E1
19(R)-hydroxy PGE0
T845282108853-39-8
13,14-Dihydro-19(R)-hydroxy Prostaglandin E1 (13,14-dihydro-19(R)-hydroxy PGE1) is posited as a theoretical metabolite resulting from the action of ω-1 hydroxylase on 13,14-dihydro PGE1. Its biosynthesis and biological activity remain unreported in scientific literature.
  • Inquiry Price
8-10 weeks
Size
QTY